Cite
HARVARD Citation
Krznaric, I. et al. (2018). Similar long‐term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV‐1‐infected patients in a retrospective, real‐life cohort of 14 years. HIV medicine. 19 (9), pp. 662-667. [Online].